- Home
- UFCS vs PHAR Comparison
UFCS vs PHAR Comparison
Compare UFCS & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- PHAR
- Stock Information
- Founded
- UFCS 1946
- PHAR 1988
- Country
- UFCS United States
- PHAR Netherlands
- Employees
- UFCS N/A
- PHAR N/A
- Industry
- UFCS Property-Casualty Insurers
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- UFCS Finance
- PHAR Health Care
- Exchange
- UFCS Nasdaq
- PHAR Nasdaq
- Market Cap
- UFCS 666.1M
- PHAR 718.1M
- IPO Year
- UFCS N/A
- PHAR N/A
- Fundamental
- Price
- UFCS $28.57
- PHAR $11.00
- Analyst Decision
- UFCS Buy
- PHAR Strong Buy
- Analyst Count
- UFCS 2
- PHAR 3
- Target Price
- UFCS $30.00
- PHAR $30.00
- AVG Volume (30 Days)
- UFCS 124.9K
- PHAR 3.0K
- Earning Date
- UFCS 08-05-2025
- PHAR 07-31-2025
- Dividend Yield
- UFCS 2.25%
- PHAR N/A
- EPS Growth
- UFCS N/A
- PHAR N/A
- EPS
- UFCS 2.54
- PHAR N/A
- Revenue
- UFCS $1,288,423,000.00
- PHAR $320,708,000.00
- Revenue This Year
- UFCS $11.31
- PHAR $13.31
- Revenue Next Year
- UFCS $10.61
- PHAR $7.68
- P/E Ratio
- UFCS $11.22
- PHAR N/A
- Revenue Growth
- UFCS 14.59
- PHAR 24.13
- 52 Week Low
- UFCS $18.04
- PHAR $6.65
- 52 Week High
- UFCS $31.70
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- UFCS 54.06
- PHAR 51.11
- Support Level
- UFCS $27.65
- PHAR $10.23
- Resistance Level
- UFCS $28.66
- PHAR $11.21
- Average True Range (ATR)
- UFCS 0.62
- PHAR 0.27
- MACD
- UFCS -0.00
- PHAR -0.14
- Stochastic Oscillator
- UFCS 63.64
- PHAR 34.01
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.